Janux Therapeutics (JANX) Profit After Tax (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Profit After Tax of -$24.4 million for Q1 2026, down 3.63% year-over-year from -$25.3 million in Q1 2025, and up 29.07% quarter-over-quarter from -$34.3 million in Q4 2025.
Janux Therapeutics (JANX) Profit After Tax (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Profit After Tax for 7 consecutive years, with -$24.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 3.63% year-over-year to -$24.4 million; the TTM figure through Mar 2026 stood at -$116.9 million (down 48.27% YoY), while the FY2025 annual figure was -$113.6 million, down 64.69% from the prior year.
- Profit After Tax rose to -$24.4 million in Q1 2026 per JANX's latest filing, from -$34.3 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$7.1 million in Q2 2024 and bottomed at -$34.3 million in Q4 2025.
- Historically, Profit After Tax has averaged -$19.6 million across 5 years, with a median of -$17.5 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 487.13% — and 2024, when it surged 60.45%.
- Janux Therapeutics' Profit After Tax stood at -$15.3 million in 2022, then gained by 20.92% to -$12.1 million in 2023, then slumped by 66.83% to -$20.2 million in 2024, then slumped by 69.89% to -$34.3 million in 2025, then grew by 29.07% to -$24.4 million in 2026.
- Business Quant data shows JANX's Profit After Tax at -$24.4 million in Q1 2026, -$34.3 million in Q4 2025, and -$24.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | -24.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.85 Mn |
| Mar 31, 2026 | -24.36 Mn |
| Dec 31, 2025 | -34.35 Mn |
| Sep 30, 2025 | -24.31 Mn |
| Jun 30, 2025 | -33.87 Mn |
| Mar 31, 2025 | -23.51 Mn |
| Dec 31, 2024 | -20.22 Mn |
| Sep 30, 2024 | -28.06 Mn |
| Jun 30, 2024 | -7.05 Mn |
| Mar 31, 2024 | -15.95 Mn |
| Dec 31, 2023 | -12.12 Mn |
| Sep 30, 2023 | -11.68 Mn |
| Jun 30, 2023 | -17.83 Mn |
| Mar 31, 2023 | -17.46 Mn |
| Dec 31, 2022 | -15.32 Mn |
| Sep 30, 2022 | -16.70 Mn |
| Jun 30, 2022 | -16.89 Mn |
| Mar 31, 2022 | -13.41 Mn |
| Dec 31, 2021 | -13.71 Mn |
| Sep 30, 2021 | -10.77 Mn |